Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart pump therapy shows promise for long COVID sufferers

NCT ID NCT07492953

Symptom relief Sponsor: National Defense Medical Center, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a non-invasive treatment called enhanced external counterpulsation (EECP) can improve heart and lung function in adults with long COVID. Ten participants received EECP therapy on one of two schedules. Researchers measured exercise capacity, symptoms, and safety to see if the therapy helps recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

10 people

The number who actually took part.

Started

Dec 2023

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 20 years * Eligible for follow-up ≥3 months * A confirmed history of COVID-19 (via PCR or antigen test) * Post-COVID-19 with persistent symptoms ( fatigue, exercise intolerance, dyspnea on exertion, and/or cognitive difficulties) for ≥3 months Exclusion Criteria: * Severe peripheral arterial disease or limb ischemia * Active deep vein thrombosis * Aortic valve regurgitation, * Aortic aneurysm requiring surgical repair * Pregnancy * Other serious cardiovascular conditions contraindicating EECP * Unable to ambulate * Severe neurocognitive impairment precluding consent or cooperation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Long COVID symptoms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Long COVID symptoms

Contacts and locations

Locations

  • Natioanl Denfense Medical University

    Taipei, 114, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.